Recording Myasthenia Gravis Symptoms With Smartphones
Uses smartphone recordings to measure symptoms in adults with myasthenia gravis.
Plain-language title generated from the registry record
Registry title: Capturing Key MG-symptoms Using Smartphone Recordings.
Key facts
- Where
- Leiden, NetherlandsSee the site
Where in Netherlands
- Leiden University Medical CenterLeiden, NetherlandsNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Leiden University Medical Center
- Trial code
- NCT06743490
- Record updated
- 8 July 2026
- Original description
This study will make use of a cross-sectional design of MG patients and non-MG participants to quantitatively assess key MG symptoms, and to explore the applicability of machine learning algorithms to their measurement.Read full original descriptionShow less
Capturing Key Symptoms Using Smartphone Recordings in Patients With Myasthenia Gravis (CAPTURE-MG)
This study will make use of a cross-sectional design of MG patients and non-MG participants to quantitatively assess key MG symptoms, and to explore the applicability of machine learning algorithms to their measurement.
Inclusion: Age ≥ 18 years; Ability to understand the requirements of the study and provide written informed consent; A clinical diagnosis of myasthenia gravis (ocular or generalized) as defined by the Dutch national guideline (category "definite" or "probable" MG); MGFA Clinical Classification of disease severity I-IV; Subjects have at least one of the symptoms of interest (namely dysarthria, dysphonia, proximal arm fatigue and/or ptosis); Subjects are not diagnosed with and have no clinical suspicion of MG; Subjects do not have a medical history of any of the symptoms of interest (namely dysarthria, dysphonia, proximal arm fatigue and/or ptosis).
Exclusion: Subjects currently taking part in a clinical trial of an Investigational Medicinal Product; Subjects who have used an immediate release pyridostigmine-based medication in the 12 hours prior to their participation and participants on prolonged release pyridostigmine; Subjects with a diagnosed neurological disease resulting in muscle weakness, other than MG; Limitation of upper limb mobility or speech impairment of any cause; Not willing to be audio-recorded for the study assessments; Not willing to be video-recorded for the study assessments; Subjects have cognitive or physical limitations that, in the opinion of the investigator, limits the subject's ability to complete study procedures/; Subjects with an upper-limb amputation or who are non-verbal.